New study confirms the existence of 'trial effect' in HIV clinical trials
July 13, 2011 in HIV & AIDSA new study by investigators from the University of North Carolina at Chapel Hill School of Medicine has confirmed the existence of a "trial effect" in clinical trials for treatment of HIV.
Trial effect is an umbrella term for the benefit experienced by study participants simply by virtue of their participating in the trial. It includes the benefit of newer and more effective treatments, the way those treatments are delivered, increased care and follow-up, and the patient's own behavior change as a result of being under observation.
"Trial effect is notoriously difficult to test," said Prema Menezes, PhD, assistant professor of medicine at UNC and lead author of the study. "Our study used the objective finding of viral load to test our hypothesis," she said.
Researchers compared viral suppression among patients who began highly active antiretroviral therapy (HAART) in a clinical trial with patients who received HAART in routine clinical care in two different time periods, 1996-1999 and 2000-2006. They found clear evidence of a trial effect during the earlier period, but not during the later period. Researchers offer that improvements to antiretroviral therapy (fewer pills and fewer side effects), and the change in attitude to HIV, which has come to be seen by many as a chronic, but treatable infection, may be among the explanations for the lack of demonstrable trial effect in the later period.
"This is the first study to clearly demonstrate a trial effect in HIV clinical trials, and this has important implications moving forward," Menezes said. Documentation of a clinical trial effect should be considered when interpreting the generalizability of clinical trial results. At the same time, the fact that no trial effect was observed in the current HAART period argues that the efficacy demonstrated in clinical trials is likely to predict the effectiveness of the therapy in broader treatment populations. Clinicians and public health officials may have increased confidence that treatment guidelines based on clinical trial data are relevant to routine clinical care.
More information: Menezes P, Miller WC, Wohl DA, Adimora AA, Leone PA, et al. (2011) Does HAART Efficacy Translate to Effectiveness? Evidence for a Trial Effect. PLoS ONE 6(7): e21824. doi:10.1371/journal.pone.0021824
Provided by
Public Library of Science
-
Gene therapy shows promise as weapon against HIV
Feb 17, 2009 |
not rated yet |
0
-
International HIV/AIDS study is halted
Jan 19, 2006 |
not rated yet |
0
-
Adaptive trial designs could accelerate HIV vaccine development
Apr 20, 2011 |
not rated yet |
0
-
Researchers present Phase II HIV gene therapy trial data at CROI 2010
Feb 19, 2010 |
not rated yet |
0
-
Study finds early HAART during TB treatment boosts survival rate in co-infected people
Jul 22, 2010 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
8 hours ago |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (3) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Mortality rates decrease, chronic disease rates increase among HIV+ ICU patients
The expanded use of antiretrovirals, potent drugs used to treat retroviral infections such as human immunodeficiency virus (HIV), has been linked to significant decreases in hospital mortality rates among severely ill HIV-positive(HIV+) ...
HIV & AIDS
May 23, 2012 |
not rated yet |
0
Newly discovered breast milk antibodies help neutralize HIV
Antibodies that help to stop the HIV virus have been found in breast milk. Researchers at Duke University Medical Center isolated the antibodies from immune cells called B cells in the breast milk of infected mothers in Malawi, ...
HIV & AIDS
May 22, 2012 |
5 / 5 (3) |
1
|
Reactions to HIV drug have autoimmune cause, reports AIDS journal
Potentially severe hypersensitivity reactions to the anti-HIV drug abacavir occur through an autoimmune mechanism, resulting from the creation of drug-induced immunogens that are attacked by the body's immune system, according ...
HIV & AIDS
May 22, 2012 |
5 / 5 (1) |
0
Is the U.S. ready for home HIV tests?
At the pharmacy, you can buy anything from tea kettles to Tylenol. But what if you could buy a rapid HIV test over the counter and test yourself in the privacy of your own home?
HIV & AIDS
May 21, 2012 |
not rated yet |
0
|
Reduced glycerin formulation of tenofovir vaginal gel safe for rectal use
A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests a study published online this week in the Journal of Antimicrobial Chemotherapy. In lab ...
HIV & AIDS
May 17, 2012 |
5 / 5 (1) |
0
Most occupational injury and illness costs are paid by the government and private payers
UC Davis researchers have found that workers' compensation insurance is not used nearly as much as it should be to cover the nation's multi-billion dollar price tag for workplace illnesses and injuries. Instead, almost 80 ...
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...
Cancer may require simpler genetic mutations than previously thought
Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...
Inherited DNA change explains overactive leukemia gene
A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.
Early physical therapist treatment associated with reduced risk of healthcare utilization and reduced overall healthcare
A new study published in Spine shows that early treatment by a physical therapist for low back pain (LBP), as compared to delayed treatment, was associated with reduced risk of subsequent healthcare utilization and lower ...
Skp2 activates cancer-promoting, glucose-processing Akt
HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.